LIGAND PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
LGND$314.15+2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Financial Statements and Supplementary Data
| Item 8. | Consolidated Financial Statements and Supplementary Data |
|---|
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 58 |
| Consolidated Balance Sheets | 59 |
| Consolidated Statements of Operations | 60 |
| Consolidated Statements of Comprehensive Income (Loss) | 61 |
| Consolidated Statements of Stockholders’ Equity | 63 |
| Consolidated Statements of Cash Flows | 63 |
| Notes to Consolidated Financial Statements | 65 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.